Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Bevacizumab is named as an intervention in 431 current clinical trials in our China, USA, UK, India and Ireland registers. 266 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Akeso (30). The most-studied condition is Colorectal Cancer.

Bevacizumab also has an approved-drug profile on this site (FDA label data): Avastin (Bevacizumab) →

Trials by status

Recruiting26662%
Not yet open7718%
Active, closed8520%
By invitation31%

Trials by phase

Phase 217741%
Phase 39322%
Phase 1/27618%
Phase 15413%
Phase 2/3153%
Not applicable72%
Observational51%
Phase 431%
Phase EARLY_PHASE110%

Clinical trials of Bevacizumab

431 trials

Study	Phase	Status	Lead sponsor	Registers
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk NCT06930573 · ClinicalTrials.gov ↗ · HCC	Phase 4	Recruiting	The First Affiliated Hospital of Zhengzhou University	China
A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer NCT07619235 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC)	Phase 4	Recruiting	Xianglin Yuan	China
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer NCT01954992 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Adenocarcinoma	Phase 3	Recruiting	Eleison Pharmaceuticals LLC.	USA
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer NCT02535221 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Peking University	China
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC NCT03303495 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms	Phase 3	Recruiting	Sun Yat-sen University	China
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer NCT04215731 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	Yanhong Deng	China
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases NCT04687631 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases	Phase 3	Recruiting	Fudan University	China
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma NCT04997837 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Fudan University	China
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer NCT05253651 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) NCT05281471 · ClinicalTrials.gov ↗ · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer	Phase 3	Recruiting	Genelux Corporation	USA
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients NCT05797467 · ClinicalTrials.gov ↗ · Colorectal Cancer, Chemotherapy Effect	Phase 3	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	China
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study NCT05862285 · ClinicalTrials.gov ↗ · Cancer	Phase 3	Recruiting	Hoffmann-La Roche	UK, China
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients NCT05899608 · Non-Small Cell Lung Cancer	Phase 3	Recruiting	Summit Therapeutics	Ireland, UK, USA, China
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma NCT06022861 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Shandong Boan Biotechnology Co., Ltd	China
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC NCT06102395 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab	Phase 3	Recruiting	Beijing Tongren Hospital	China
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer NCT06459687 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Recruiting	Lee's Pharmaceutical Limited	China
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients NCT06497985 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Chipscreen Biosciences, Ltd.	China
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) NCT06601335 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	Akeso	China
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma NCT06618664 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer NCT06662786 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, India, China
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases NCT06699212 · Recurrent Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	Rakuten Medical, Inc.	USA, China
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy NCT06750094 · Colorectal Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, India, China
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer NCT06764875 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 NCT06767514 · Non-Small Cell Lung Cancer	Phase 3	Recruiting	Summit Therapeutics	USA, China
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer NCT06767527 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer (TNBC)	Phase 3	Recruiting	Akeso	China
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC NCT06791512 · ClinicalTrials.gov ↗ · Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum	Phase 3	Recruiting	Jun Huang	China
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma NCT06793917 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Fujian Cancer Hospital	China
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) NCT06819007 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	Daiichi Sankyo	UK, USA, India, China
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) NCT06824467 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer NCT06901531 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer	Phase 3	Recruiting	Astellas Pharma Global Development, Inc.	UK, USA, China
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma NCT06921785 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer NCT06951503 · ClinicalTrials.gov ↗ · Colorectal Adenocarcinoma	Phase 3	Recruiting	Akeso	China
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer NCT06954584 · Ovarian Cancer	Phase 3	Recruiting	Tongji Hospital	China
Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer NCT06992648 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic, Colorectal Cancer Recurrent	Phase 3	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) NCT06997497 · Colon Adenocarcinoma, Rectal Adenocarcinoma	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma NCT07002346 · ClinicalTrials.gov ↗ · Ovarian Clear Cell Carcinoma	Phase 3	Recruiting	Tongji Hospital	China
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy NCT07010263 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 3	Recruiting	Akeso	China
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT07043400 · ClinicalTrials.gov ↗ · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	BeOne Medicines	UK, USA, China
FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma NCT07058428 · ClinicalTrials.gov ↗ · Multiple Brain Metastases in Lung Adenocarcinoma	Phase 3	Recruiting	Sun Yat-Sen University Cancer Center	China
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer NCT07213804 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms	Phase 3	Recruiting	Eli Lilly and Company	Ireland, UK, USA, China
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) NCT07216703 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, India
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer NCT07222800 · ClinicalTrials.gov ↗ · Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms	Phase 3	Recruiting	Pfizer	USA, China
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy NCT07225270 · ClinicalTrials.gov ↗ · Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC	Phase 3	Recruiting	Genmab	USA
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer NCT07228832 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 3	Recruiting	Summit Therapeutics	UK, USA, China
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer NCT07284849 · ClinicalTrials.gov ↗ · CRC (Colorectal Cancer)	Phase 3	Recruiting	Incyte Corporation	UK, USA, China
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558 · Ovarian Neoplasms, Ovarian Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer NCT07409272 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma	Phase 3	Recruiting	Astellas Pharma Global Development, Inc.	UK, USA, China
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer NCT07412613 · ClinicalTrials.gov ↗ · Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer	Phase 3	Recruiting	Akeso	China
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 NCT07431281 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases NCT07481786 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma, Brain Metastases, Radiotherapy, Intensity-Modulated	Phase 3	Recruiting	Sun Yat-sen University	China
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer NCT07525206 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	AbbVie	USA, China
SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC NCT07549399 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma, High-Risk Cancer, MSS	Phase 3	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	China
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) NCT07549412 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 3	Recruiting	EMD Serono Research & Development Institute, Inc.	UK, USA, China
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer NCT07564141 · ClinicalTrials.gov ↗ · Platinum-Sensitive Ovarian Cancer, Ovarian Cancer	Phase 3	Recruiting	Genmab	USA
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) NCT07566156 · ClinicalTrials.gov ↗ · Urothelial Cancer, Urinary Bladder Neoplasms	Phase 3	Recruiting	Astellas Pharma Global Development, Inc.	USA
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) NCT07582315 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure NCT07606599 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) NCT07621718 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc.	USA
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer NCT07673887 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 3	Recruiting	Astellas Pharma Global Development, Inc.	USA
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer NCT07722494 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Innovent Biologics (Suzhou) Co. Ltd.	China
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) NCT07776691 · ClinicalTrials.gov ↗ · Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	USA
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer NCT06123884 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2/3	Recruiting	Bio-Thera Solutions	China
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients NCT06280495 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases	Phase 2/3	Recruiting	Sun Yat-sen University	China
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer NCT06441565 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2/3	Recruiting	Sun Yat-sen University	China
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer NCT07221357 · ClinicalTrials.gov ↗ · Untreated, Unresectable, or Metastatic Colorectal Cancer	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma NCT07490301 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma, PDAC	Phase 2/3	Recruiting	AbbVie	UK, USA, China
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) NCT07554456 · Esophageal Squamous Cell Carcinoma	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
Pan Tumor Rollover Study NCT03899155 · Cancer	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China
A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma NCT04250064 · ClinicalTrials.gov ↗ · DIPG	Phase 2	Recruiting	Tata Memorial Centre	India
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction NCT04840264 · ClinicalTrials.gov ↗ · Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis	Phase 2	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	China
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC NCT05192798 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 2	Recruiting	The First Affiliated Hospital of Bengbu Medical University	China
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer NCT05200260 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma	Phase 2	Recruiting	Shanghai Gynecologic Oncology Group	China
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy NCT05468242 · ClinicalTrials.gov ↗ · Stage III Non-small Cell Lung Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) NCT05489211 · ClinicalTrials.gov ↗ · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma NCT05512351 · ClinicalTrials.gov ↗ · Oligodendroglioma	Phase 2	Recruiting	Henan Provincial People's Hospital	China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Breast Tumors	Phase 2	Recruiting	Fudan University	China
SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor	Phase 2	Recruiting	Fudan University	China
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer NCT05628038 · ClinicalTrials.gov ↗ · Recurrent Rectal Cancer	Phase 2	Recruiting	Fudan University	China
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT05702229 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients NCT05727163 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Sun Yat-sen University	China
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Biliary Tract Cancer	Phase 2	Recruiting	Replimune, Inc.	USA
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial NCT05862168 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma	Phase 2	Recruiting	Weijia Fang, MD	China
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study NCT06125080 · ClinicalTrials.gov ↗ · TNBC - Triple-Negative Breast Cancer	Phase 2	Recruiting	Huihua Xiong	China
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing NCT06145308 · ClinicalTrials.gov ↗ · Salivary Gland Carcinoma, Precision Therapy	Phase 2	Recruiting	Peking Union Medical College	China
A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC NCT06177925 · ClinicalTrials.gov ↗ · Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site	Phase 2	Recruiting	Nanfang Hospital, Southern Medical University	China
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer NCT06218810 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation	Phase 2	Recruiting	Fudan University	China
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 NCT06219941 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) NCT06276283 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Dizal Pharmaceuticals	China
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer NCT06282445 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	China
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer NCT06293014 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Henan Cancer Hospital	China
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer NCT06341296 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	West China Hospital	China
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC NCT06360042 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer NCT06402435 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Hubei Cancer Hospital	China
A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma NCT06444009 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Lei Liu	China
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer NCT06491472 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients NCT06493760 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	China
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety NCT06531278 · ClinicalTrials.gov ↗ · Pancreatic Cancer Metastatic to Liver	Phase 2	Recruiting	Jiang Long	China
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607 · ClinicalTrials.gov ↗ · Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	Phase 2	Recruiting	AstraZeneca	UK, USA, China
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab NCT06540326 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma NCT06558227 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer NCT06560112 · ClinicalTrials.gov ↗ · Recurrent Ovarian Cancer	Phase 2	Recruiting	Akeso	China
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM NCT06590259 · ClinicalTrials.gov ↗ · Colorectal Cancer Liver Metastasis	Phase 2	Recruiting	Shanghai 6th People's Hospital	China
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease NCT06607458 · ClinicalTrials.gov ↗ · Refractory Metastatic Colorectal Cancer	Phase 2	Recruiting	Delcath Systems Inc.	USA
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer NCT06686030 · ClinicalTrials.gov ↗ · Platinum-sensitive Ovarian Cancer	Phase 2	Recruiting	Akeso	China
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab NCT06701656 · ClinicalTrials.gov ↗ · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)	Phase 2	Recruiting	PPD Development, LP	USA
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) NCT06703073 · ClinicalTrials.gov ↗ · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)	Phase 2	Recruiting	PPD Development, LP	USA
Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study NCT06728865 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, Brain Metastases	Phase 2	Recruiting	Li-kun Chen	China
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer NCT06735326 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC NCT06742424 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC)	Phase 2	Recruiting	West China Hospital	China
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression NCT06749860 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer NCT06764680 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy	Phase 2	Recruiting	Sun Yat-sen University	China
A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC NCT06769295 · ClinicalTrials.gov ↗ · Lung Cancer, Non-Small Cell	Phase 2	Recruiting	Sichuan University	China
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC NCT06769971 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	Sichuan University	China
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC NCT06786026 · ClinicalTrials.gov ↗ · TNBC, Triple Negative Breast Cancer	Phase 2	Recruiting	Fudan University	China
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer NCT06787612 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 2	Recruiting	Regeneron Pharmaceuticals	USA
Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer NCT06791148 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer NCT06792695 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China
Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma NCT06801730 · ClinicalTrials.gov ↗ · Glioma	Phase 2	Recruiting	Zhifeng Tian,MD	China
Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer NCT06802666 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer, Neoadjuvant Therapy	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer NCT06820463 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	AbbVie	UK, USA
Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases NCT06848842 · ClinicalTrials.gov ↗ · Colorectal Liver Metastases	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer NCT06856187 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 2	Recruiting	Fudan University	China
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. NCT06890338 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 2	Recruiting	AbbVie	USA
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors NCT06895928 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers NCT06906341 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms	Phase 2	Recruiting	Corcept Therapeutics	USA
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer NCT06944106 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer NCT06948448 · Colorectal Cancer	Phase 2	Recruiting	Ono Pharmaceutical Co., Ltd.	USA
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) NCT06951646 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)	Phase 2	Recruiting	Second Xiangya Hospital of Central South University	China
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma NCT07012798 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies NCT07024784 · ClinicalTrials.gov ↗ · Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer	Phase 2	Recruiting	AbbVie	USA
Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study NCT07047560 · ClinicalTrials.gov ↗ · Colorectal Cancer (CRC)	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. NCT07052253 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Akeso	China
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer NCT07059845 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 2	Recruiting	AbbVie	USA
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study NCT07065435 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma NCT07069712 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	AstraZeneca	UK, USA, China
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC NCT07085169 · ClinicalTrials.gov ↗ · Colo-rectal Cancer, Third-line and Beyond Therapy, TAS 102	Phase 2	Recruiting	Ruijin Hospital	China
Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial NCT07106034 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Phase 2	Recruiting	Shanghai Pudong Hospital	China
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] NCT07111546 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer NCT07114315 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Akeso	China
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer NCT07150247 · ClinicalTrials.gov ↗ · BRAF V600 Colorectal Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC NCT07157969 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 2	Recruiting	Peking Union Medical College Hospital	China
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer NCT07162714 · ClinicalTrials.gov ↗ · Rectal Cancer, Radiation, AK112	Phase 2	Recruiting	Zhejiang Cancer Hospital	China
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma NCT07179900 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma NCT07188103 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Anhui Provincial Hospital	China
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma NCT07297212 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma	Phase 2	Recruiting	BioNTech SE	China
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma NCT07317414 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	Peking Union Medical College Hospital	China
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT NCT07327788 · ClinicalTrials.gov ↗ · Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin, Bevacizumab	Phase 2	Recruiting	Nanfang Hospital, Southern Medical University	China
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] NCT07331155 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07381075 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	West China Hospital	China
ctDNA-guided Treatment Decision-making NCT07394218 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer ( HER2 Negative), ctDNA	Phase 2	Recruiting	Fudan University	China
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression NCT07412262 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Guangdong Association of Clinical Trials	China
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies NCT07415031 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 2	Recruiting	Mirati Therapeutics Inc.	UK, USA, China
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer NCT07446322 · Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer	Phase 2	Recruiting	Oncolytics Biotech	USA
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study NCT07446452 · ClinicalTrials.gov ↗ · HER2-low Breast Cancer	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer NCT07474727 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Multitude Therapeutics Inc.	China
JS212 Combination Therapies in Metastatic Colorectal Cancer NCT07503756 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma NCT07518602 · ClinicalTrials.gov ↗ · Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)	Phase 2	Recruiting	Sun Yat-sen University	China
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer NCT07527858 · ClinicalTrials.gov ↗ · Advanced Microsatellite Stable Colorectal Cancer	Phase 2	Recruiting	Gilead Sciences	USA
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States NCT07554521 · ClinicalTrials.gov ↗ · Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	BeOne Medicines	USA
A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer NCT07562490 · ClinicalTrials.gov ↗ · ctDNA, Chemotherapy, Colorectal Cancer	Phase 2	Recruiting	Fudan University	China
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer NCT07591090 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Phase 2	Recruiting	Akeso	China
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases NCT07623577 · ClinicalTrials.gov ↗ · TNBC, Brain Metastasis	Phase 2	Recruiting	Fudan University	China
Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM. NCT07638852 · ClinicalTrials.gov ↗ · TNBC, Triple Negative Breast Cancer, Brain Metastasases	Phase 2	Recruiting	Fudan University	China
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer NCT07669779 · ClinicalTrials.gov ↗ · Advanced Non Small Cell Lung Cancer (NSCLC)	Phase 2	Recruiting	Akeso	China
Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression NCT07670026 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma NCT07700667 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial NCT07722754 · ClinicalTrials.gov ↗ · Colorectal Neoplasms Malignant, Neoplasm, Metastatic	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer NCT07797816 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients NCT07809893 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Bevacizumab in the Treatment of HHT NCT07828015 · ClinicalTrials.gov ↗ · Bevacizimab, HHT	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer NCT07831993 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer NCT03424005 · Metastatic Breast Cancer	Phase 1/2	Recruiting	Hoffmann-La Roche	UK, USA
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors NCT05101070 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1/2	Recruiting	Shionogi	USA
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab NCT05319639 · ClinicalTrials.gov ↗ · Gastric Cancer Stage IV	Phase 1/2	Recruiting	Fujian Cancer Hospital	China
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer NCT05379595 · ClinicalTrials.gov ↗ · Advanced or Metastatic Colorectal Cancer	Phase 1/2	Recruiting	Janssen Research & Development, LLC	USA, China
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma NCT05440708 · Hepatocellular Carcinoma	Phase 1/2	Recruiting	Tvardi Therapeutics, Incorporated	USA
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366 · ClinicalTrials.gov ↗ · High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma	Phase 1/2	Recruiting	Genmab	USA, China
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors NCT05584670 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Sanofi	USA
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors NCT05689853 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 1/2	Recruiting	Akeso	China
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer NCT05739981 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 1/2	Recruiting	Imunon	USA
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors NCT05797168 · ClinicalTrials.gov ↗ · Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer	Phase 1/2	Recruiting	AstraZeneca	UK, USA, China
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) NCT05824975 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)	Phase 1/2	Recruiting	GI Innovation, Inc.	USA
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. NCT05867420 · Advanced Solid Tumors	Phase 1/2	Recruiting	AskGene Pharma, Inc.	USA, China
FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264 · ClinicalTrials.gov ↗ · Cancer, Colorectal Cancer, Solid Tumor	Phase 1/2	Recruiting	Parabilis Medicines, Inc.	USA
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379 · ClinicalTrials.gov ↗ · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult	Phase 1/2	Recruiting	Neonc Technologies, Inc.	USA
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients NCT06202001 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 1/2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma NCT06427239 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1/2	Recruiting	Fudan University	China
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors NCT06427941 · ClinicalTrials.gov ↗ · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer	Phase 1/2	Recruiting	BeOne Medicines	USA, China
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409 · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors NCT06445062 · ClinicalTrials.gov ↗ · Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Revolution Medicines, Inc.	USA
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) NCT06469944 · ClinicalTrials.gov ↗ · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer NCT06512051 · ClinicalTrials.gov ↗ · Advanced or Metastatic Non-small Cell Lung Cancer	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) NCT06530251 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 1/2	Recruiting	Akeso	China
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors NCT06697197 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	Bristol-Myers Squibb	USA
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis NCT06718933 · ClinicalTrials.gov ↗ · Breast Cancer Metastatic, Breast Cancer Brain Metastases	Phase 1/2	Recruiting	Fudan University	China
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111 · Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) NCT06796907 · ClinicalTrials.gov ↗ · Tumours, Gynecological	Phase 1/2	Recruiting	GlaxoSmithKline	UK, USA
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis NCT06809517 · Leptomeningeal Metastasis, Intrathecal Drug Delivery	Phase 1/2	Recruiting	Guangzhou Medical University	China
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer NCT06840002 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) NCT06843447 · ClinicalTrials.gov ↗ · Ovarian Cancer Recurrent	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA
Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) NCT06844422 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1/2	Recruiting	Shandong Cancer Hospital and Institute	China
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer NCT06859775 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Cervical Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors NCT06877650 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors	Phase 1/2	Recruiting	Shanghai JMT-Bio Inc.	China
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer NCT06938321 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 1/2	Recruiting	Akeso	China
AK129 Combination Therapy for Advanced Solid Tumors NCT06943820 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma	Phase 1/2	Recruiting	Akeso	China
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors NCT06953323 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Wigen Biomedicine Technology (Shanghai) Co., Ltd.	China
Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma NCT06995105 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma (HCC)	Phase 1/2	Recruiting	Zhejiang University	China
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC NCT07012954 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 1/2	Recruiting	Sun Yat-sen University	China
A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer NCT07042802 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer NCT07056777 · ClinicalTrials.gov ↗ · Gastrointestinal Cancer	Phase 1/2	Recruiting	Zhejiang Doer Biologics Co., Ltd.	China
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer NCT07059221 · ClinicalTrials.gov ↗ · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer NCT07079631 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 1/2	Recruiting	BioNTech SE	UK, USA
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer NCT07080216 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 1/2	Recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
A Study of YL242 in Subjects With Advanced Solid Tumors NCT07197827 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	USA, China
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors NCT07256782 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Qilu Pharmaceutical Co., Ltd.	China
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors NCT07397338 · Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC)	Phase 1/2	Recruiting	Revolution Medicines, Inc.	USA
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) NCT07479485 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 1/2	Recruiting	Lepu Biopharma Co., Ltd.	China
AMT-116 in Combination With AK112 in Patients With Lung Cancer NCT07590531 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer (NSCLC)	Phase 1/2	Recruiting	Multitude Therapeutics Inc.	China
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) NCT07602855 · ClinicalTrials.gov ↗ · Neoplasms, Lung	Phase 1/2	Recruiting	GlaxoSmithKline	USA
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer NCT07623356 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 1/2	Recruiting	Akeso	China
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors NCT07730021 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors	Phase 1/2	Recruiting	Astellas Pharma Global Development, Inc.	USA
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas NCT03715933 · ClinicalTrials.gov ↗ · Ewing Sarcoma, Colorectal Adenocarcinoma	Phase 1	Recruiting	Inhibrx Biosciences, Inc	UK, USA
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer NCT04516447 · ClinicalTrials.gov ↗ · Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer	Phase 1	Recruiting	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	USA
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) NCT04929223 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 1	Recruiting	Hoffmann-La Roche	UK, USA
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan NCT05005403 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer	Phase 1	Recruiting	AbbVie	USA
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) NCT05067283 · Advanced Solid Tumors	Phase 1	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer NCT05365581 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc.	USA, China
A Study of ASP3082 in Adults With Advanced Solid Tumors NCT05382559 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	Astellas Pharma Inc	USA, China
A Study of ASP1002 in Adults for Treatment of Solid Tumors NCT05719558 · Advanced Solid Tumors	Phase 1	Recruiting	Astellas Pharma Global Development, Inc.	USA
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors NCT05836324 · ClinicalTrials.gov ↗ · Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors	Phase 1	Recruiting	Incyte Corporation	UK, USA, China
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors NCT06004245 · Advanced Solid Tumors, Colorectal Cancer	Phase 1	Recruiting	Vividion Therapeutics, Inc.	UK, USA, China
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 NCT06084481 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers	Phase 1	Recruiting	AbbVie	USA, China
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms	Phase 1	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, China
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors NCT06233942 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	BeOne Medicines	USA, China
First In Human Study of CX-2051 in Advanced Solid Tumors NCT06265688 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 1	Recruiting	CytomX Therapeutics	USA
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors NCT06336707 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors NCT06400472 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms	Phase 1	Recruiting	Eli Lilly and Company	USA
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers NCT06469281 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer	Phase 1	Recruiting	Regeneron Pharmaceuticals	USA
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) NCT06551142 · ClinicalTrials.gov ↗ · Neoplasms	Phase 1	Recruiting	GlaxoSmithKline	UK, USA
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors NCT06586515 · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Recruiting	Eli Lilly and Company	Ireland, USA, China
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer	Phase 1	Recruiting	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	USA
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors NCT06657144 · Metastatic Solid Tumor, Advanced Solid Tumor	Phase 1	Recruiting	Coherus Oncology, Inc.	USA, China
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers NCT06663319 · Colorectal Neoplasms, Gastrointestinal Neoplasms	Phase 1	Recruiting	Janssen Research & Development, LLC	USA
A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer NCT06717880 · ClinicalTrials.gov ↗ · Advanced Malignancies	Phase 1	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer NCT06825624 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies NCT06839105 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor	Phase 1	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors NCT06859762 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	USA, China
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC NCT06868732 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer	Phase 1	Recruiting	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer NCT07024615 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc.	USA
Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases NCT07117435 · ClinicalTrials.gov ↗ · Colorectal Liver Metastases, First-line Treatment	Phase 1	Recruiting	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	China
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors NCT07277270 · ClinicalTrials.gov ↗ · Neoplasms	Phase 1	Recruiting	GlaxoSmithKline	USA
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer NCT07278336 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1	Recruiting	AbbVie	USA, China
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer	Phase 1	Recruiting	Pfizer	USA
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer NCT07381829 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer	Phase 1	Recruiting	HC Biopharma Inc.	China
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. NCT07470853 · ClinicalTrials.gov ↗ · PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer	Phase 1	Recruiting	Whitehawk Therapeutics, Inc.	USA
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma NCT07478302 · ClinicalTrials.gov ↗ · Advanced Unresectable Hepatocellular Carcinoma	Phase 1	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma NCT07557251 · ClinicalTrials.gov ↗ · Advanced HBV-Related Hepatocellular Carcinoma	Phase 1	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer NCT07359040 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors	Observational	Recruiting	Peking University People's Hospital	China
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer NCT05424692 · ClinicalTrials.gov ↗ · Colon Cancer, Rectal Cancer, Chemotherapy Effect	Not applicable	Recruiting	Peking Union Medical College Hospital	China
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT NCT05984511 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus	Not applicable	Recruiting	Third Affiliated Hospital, Sun Yat-Sen University	China
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases NCT06265350 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Liver Cancer Stage IV, Pulmonary Metastases	Not applicable	Recruiting	Sun Yat-sen University	China
Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain NCT06747728 · ClinicalTrials.gov ↗ · Brain Glioma	Not applicable	Recruiting	The First Affiliated Hospital of Zhengzhou University	China
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer NCT07466238 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC)	Not applicable	Recruiting	Peking University	China
Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC) NCT07627347 · ClinicalTrials.gov ↗ · ESCC	Not applicable	Recruiting	Nanfang Hospital, Southern Medical University	China
The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults NCT06876701 · ClinicalTrials.gov ↗ · Acute Leukemia	Phase EARLY_PHASE1	Not yet open	Ruijin Hospital	China
Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study NCT07004335 · ClinicalTrials.gov ↗ · PD-(L)1, CTLA-4, Advanced Melanoma	Phase 4	Not yet open	Hebei Medical University Fourth Hospital	China
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations NCT05767892 · ClinicalTrials.gov ↗ · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 3	Not yet open	Suzhou Puhe Pharmaceutical Technology Co., LTD	China
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC NCT05780294 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Leucogen, Chemotherapy	Phase 3	Not yet open	Sun Yat-sen University	China
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma NCT07691762 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC NCT07729605 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC)	Phase 3	Not yet open	Sun Yat-sen University	China
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer NCT07779538 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy NCT07803783 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 3	Not yet open	MediLink Therapeutics (Suzhou) Co., Ltd.	China
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular NCT07813572 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Not yet open	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer NCT07816666 · ClinicalTrials.gov ↗ · Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer	Phase 3	Not yet open	AstraZeneca	USA, India, China
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer NCT07821606 · ClinicalTrials.gov ↗ · Platinum-sensitive Recurrent Ovarian Cancer	Phase 3	Not yet open	Hansoh BioMedical R&D Company	China
JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer NCT07823348 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Not yet open	Shanghai Junshi Bioscience Co., Ltd.	China
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC NCT04890522 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Metastasis, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma NCT05976568 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2/3	Not yet open	Qilu Pharmaceutical Co., Ltd.	China
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment NCT06662877 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Second Line Treatment, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma NCT07392866 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2/3	Not yet open	Nanjing Sanhome Pharmaceutical, Co., Ltd.	China
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer NCT07585279 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line	Phase 2/3	Not yet open	Hebei Medical University Fourth Hospital	China
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma NCT05502991 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 2	Not yet open	Henan Provincial People's Hospital	China
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma NCT05518994 · ClinicalTrials.gov ↗ · Astrocytoma of Brain	Phase 2	Not yet open	Henan Provincial People's Hospital	China
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma NCT05540275 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma	Phase 2	Not yet open	Henan Provincial People's Hospital	China
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation NCT06041490 · ClinicalTrials.gov ↗ · Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma	Phase 2	Not yet open	Peking Union Medical College Hospital	China
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer NCT06063070 · ClinicalTrials.gov ↗ · Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer	Phase 2	Not yet open	Sun Yat-sen University	China
The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer NCT06092242 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Not yet open	The Second Affiliated Hospital of Shandong First Medical University	China
A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma NCT06196775 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Not yet open	Harbin Medical University	China
Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer NCT06365008 · ClinicalTrials.gov ↗ · Unresectable/Metastatic Gastric Cancer	Phase 2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer NCT06593548 · ClinicalTrials.gov ↗ · CRC, MSS, Metastatic Cancer	Phase 2	Not yet open	Fudan University	China
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC NCT06648525 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 2	Not yet open	Harbin Medical University	China
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC NCT06684158 · ClinicalTrials.gov ↗ · GC/GEJC	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN) NCT06684873 · ClinicalTrials.gov ↗ · NSCLC, Brain Metastasases	Phase 2	Not yet open	Sun Yat-sen University	China
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer NCT06713057 · ClinicalTrials.gov ↗ · Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer	Phase 2	Not yet open	West China Hospital	China
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM NCT06788171 · ClinicalTrials.gov ↗ · Colorectal Cancer Liver Metastasis	Phase 2	Not yet open	Fujian Cancer Hospital	China
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma NCT06814067 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC	Phase 2	Not yet open	Fudan University	China
Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer NCT06872606 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma	Phase 2	Not yet open	Sir Run Run Shaw Hospital	China
Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies NCT06993025 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis NCT07007728 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver	Phase 2	Not yet open	Peking University Cancer Hospital & Institute	China
Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC NCT07070713 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy	Phase 2	Not yet open	Fujian Cancer Hospital	China
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC NCT07086326 · ClinicalTrials.gov ↗ · NSCLC, Neoadjuvant Therapy, Immunotherapy	Phase 2	Not yet open	Yang Fan, MD	China
Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/GEJ Adenocarcinoma NCT07091227 · ClinicalTrials.gov ↗ · Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	Peking Union Medical College Hospital	China
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC NCT07116577 · ClinicalTrials.gov ↗ · mCRC	Phase 2	Not yet open	Jinan Central Hospital	China
Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker NCT07120451 · ClinicalTrials.gov ↗ · Advanced Ovarian Cancer	Phase 2	Not yet open	Fudan University	China
T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis NCT07150208 · ClinicalTrials.gov ↗ · Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer	Phase 2	Not yet open	Fudan University	China
AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment NCT07158840 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Not yet open	Akeso	China
High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC NCT07182708 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma	Phase 2	Not yet open	Peking University Cancer Hospital & Institute	China
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation NCT07229846 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Not yet open	Yanqiao Zhang	China
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers NCT07233850 · ClinicalTrials.gov ↗ · Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 2	Not yet open	Shenyang Sunshine Pharmaceutical Co., LTD.	China
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer NCT07244926 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer NCT07244965 · ClinicalTrials.gov ↗ · LOCALLY ADVANCED CERVICAL CANCERS	Phase 2	Not yet open	Women's Hospital School Of Medicine Zhejiang University	China
Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer NCT07286695 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC), Colorectal Cancer	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer NCT07314619 · ClinicalTrials.gov ↗ · Platinum-resistant Recurrent Ovarian Cancer (PROC)	Phase 2	Not yet open	The First Affiliated Hospital of Zhengzhou University	China
Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma NCT07374250 · ClinicalTrials.gov ↗ · Gastric Cancer, RCT	Phase 2	Not yet open	Sichuan University	China
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer NCT07497074 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2	Not yet open	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma NCT07514793 · ClinicalTrials.gov ↗ · Mesothelioma	Phase 2	Not yet open	Fudan University	China
SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer NCT07535632 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities NCT07630077 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Not yet open	Sun Yat-sen University	China
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma NCT07636772 · ClinicalTrials.gov ↗ · Urothelial Carcinoma (UC)	Phase 2	Not yet open	Akeso	China
Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer NCT07663513 · ClinicalTrials.gov ↗ · Ovarian Cancers	Phase 2	Not yet open	Fudan University	China
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer NCT07712094 · ClinicalTrials.gov ↗ · Neuroendocrine Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM NCT07728019 · ClinicalTrials.gov ↗ · CRC (Colorectal Cancer)	Phase 2	Not yet open	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer NCT07776171 · ClinicalTrials.gov ↗ · Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)	Phase 2	Not yet open	Sun Yat-sen University	China
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC NCT07819591 · ClinicalTrials.gov ↗ · SCLC, Recurrent	Phase 2	Not yet open	Shaodong Hong	China
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment NCT06370754 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1/2	Not yet open	Fudan University	China
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer NCT06990516 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Not yet open	Tongji Hospital	China
A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases NCT07357220 · ClinicalTrials.gov ↗ · Colorectal Cancer With Hepatic Metastases	Phase 1/2	Not yet open	Akeso	China
IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer NCT07361991 · ClinicalTrials.gov ↗ · Advan'ce'd, Advanced	Phase 1/2	Not yet open	The First Affiliated Hospital of Zhengzhou University	China
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer NCT07560124 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1/2	Not yet open	Akeso	China
A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer NCT07653685 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1/2	Not yet open	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	China
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation NCT07678593 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation	Phase 1/2	Not yet open	Genfleet Therapeutics (Shanghai) Inc.	China
A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer NCT07737600 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Phase 1/2	Not yet open	Lepu Biopharma Co., Ltd.	China
A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer NCT07750041 · ClinicalTrials.gov ↗ · Unresectable Advanced or Metastatic Colorectal Cancer	Phase 1/2	Not yet open	CSPC Megalith Biopharmaceutical Co.,Ltd.	China
Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma NCT07761286 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 1/2	Not yet open	CSPC Megalith Biopharmaceutical Co.,Ltd.	China
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors NCT07774611 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Not yet open	Hangzhou Sumgen Biotech Co., Ltd.	China
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma NCT07791758 · ClinicalTrials.gov ↗ · Metastatic Colorectal Carcinoma	Phase 1/2	Not yet open	Nanjing Leads Biolabs Co.,Ltd	China
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC NCT06913218 · ClinicalTrials.gov ↗ · Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma	Phase 1	Not yet open	Akeso	China
OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors NCT07650825 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors NCT07824934 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors	Phase 1	Not yet open	Sunshine Lake Pharma Co., Ltd.	China
Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis NCT05354674 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases	Observational	Not yet open	Fudan University	China
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC NCT07093762 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Observational	Not yet open	Fuzhou General Hospital	China
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer NCT07441369 · ClinicalTrials.gov ↗ · Liver Metastases From Colorectal Cancer (mCRC)	Phase 2	By invitation	Fudan University	China
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma NCT06424626 · ClinicalTrials.gov ↗ · Melanoma, Mucosal Melanoma, Metastatic Melanoma	Phase 1	By invitation	Peking University Cancer Hospital & Institute	China
Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer NCT06849362 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC), MSS Metastatic Colorectal Cancer, Immunotherapy	Observational	By invitation	Yue Gou	China
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) NCT03148418 · ClinicalTrials.gov ↗ · Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients NCT03390686 · ClinicalTrials.gov ↗ · Lung Cancer, Non-small Cell Lung Cancer	Phase 3	Active, closed	Prestige Biopharma Limited	India
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. NCT03504397 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer	Phase 3	Active, closed	Astellas Pharma Global Development, Inc.	UK, USA, China
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients NCT03737643 · ClinicalTrials.gov ↗ · Advanced Ovarian Cancer	Phase 3	Active, closed	AstraZeneca	USA, China
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study NCT03768063 · ClinicalTrials.gov ↗ · Cancer	Phase 3	Active, closed	Hoffmann-La Roche	USA
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma NCT03778957 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Active, closed	AstraZeneca	USA, India, China
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment NCT03847428 · Hepatocellular Carcinoma	Phase 3	Active, closed	AstraZeneca	USA, India, China
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) NCT04008030 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) NCT04241185 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC NCT04550260 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Active, closed	AstraZeneca	USA, China
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer NCT04607421 · ClinicalTrials.gov ↗ · Neoplasms	Phase 3	Active, closed	Pfizer	UK, USA, India, China
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE NCT04919226 · ClinicalTrials.gov ↗ · Neuroendocrine Tumors	Phase 3	Active, closed	ITM Solucin GmbH	UK, USA, India, China
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders NCT05112861 · ClinicalTrials.gov ↗ · Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration	Phase 3	Active, closed	Outlook Therapeutics, Inc.	USA
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) NCT05112965 · ClinicalTrials.gov ↗ · Neoplasms	Phase 3	Active, closed	Hoffmann-La Roche	China
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). NCT05116189 · ClinicalTrials.gov ↗ · Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM NCT05118776 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma	Phase 3	Active, closed	Ascletis Pharmaceuticals Co., Ltd.	China
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers NCT05152147 · ClinicalTrials.gov ↗ · Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma	Phase 3	Active, closed	Jazz Pharmaceuticals	Ireland, UK, India, China
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer NCT05171660 · ClinicalTrials.gov ↗ · Colorectal Cancer Stage IV	Phase 3	Active, closed	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Phase 3 Clinical Study of AK112 for NSCLC Patients NCT05184712 · ClinicalTrials.gov ↗ · Non-Squamous Non-small Cell Lung Cancer	Phase 3	Active, closed	Akeso	China
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) NCT05239741 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	China
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer NCT05445778 · ClinicalTrials.gov ↗ · Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	Phase 3	Active, closed	AbbVie	Ireland, UK, USA, China
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) NCT05904886 · Hepatocellular Carcinoma	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China
Phase III Study of AK112 for NSCLC Patients NCT06396065 · ClinicalTrials.gov ↗ · Non-Squamous Non-small Cell Lung Cancer	Phase 3	Active, closed	Summit Therapeutics	UK, USA
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) NCT06625320 · ClinicalTrials.gov ↗ · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 3	Active, closed	Revolution Medicines, Inc.	USA
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA NCT02135042 · ClinicalTrials.gov ↗ · EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7	Phase 2/3	Active, closed	NRG Oncology	China
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) NCT03178552 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2/3	Active, closed	Hoffmann-La Roche	USA, China
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer NCT05141721 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 2/3	Active, closed	Seattle Project Corporation	USA
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) NCT06109272 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2/3	Active, closed	AbbVie	USA, China
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma NCT02519348 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Active, closed	MedImmune LLC	USA, China
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer NCT03505320 · ClinicalTrials.gov ↗ · Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer	Phase 2	Active, closed	Astellas Pharma Global Development, Inc.	USA
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) NCT04379596 · Gastric Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer NCT04390399 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Active, closed	ImmunityBio, Inc.	USA
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers NCT04430738 · Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	USA
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC NCT04736823 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Active, closed	Akeso	China
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors NCT04931342 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer NCT05009069 · Rectal Neoplasms, Rectal Cancer	Phase 2	Active, closed	Hoffmann-La Roche	China
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer NCT05227664 · ClinicalTrials.gov ↗ · Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer	Phase 2	Active, closed	Akeso	China
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer NCT05382442 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Active, closed	Akeso	USA, China
Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation NCT05491811 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Active, closed	Sun Yat-sen University	China
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer NCT05585814 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Active, closed	Shanghai Changzheng Hospital	China
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients NCT05751187 · ClinicalTrials.gov ↗ · Non-squamous NSCLC	Phase 2	Active, closed	Shanghai Chest Hospital	China
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer NCT05775159 · Hepatocellular Carcinoma, Biliary Tract Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer	Phase 2	Active, closed	Taiho Oncology, Inc.	USA
Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer NCT05969899 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Active, closed	Fudan University	China
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE NCT06040099 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Active, closed	AstraZeneca	USA
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma NCT06061809 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 2	Active, closed	ImmunityBio, Inc.	USA
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis NCT06096779 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Active, closed	Genentech, Inc.	USA
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation NCT06106308 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation	Phase 2	Active, closed	Cardiff Oncology	USA
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab NCT06107413 · ClinicalTrials.gov ↗ · Unresectable Metastatic Colorectal Cancer	Phase 2	Active, closed	AbbVie	USA
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors NCT06271837 · ClinicalTrials.gov ↗ · Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)	Phase 2	Active, closed	AstraZeneca	China
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients NCT06313970 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Active, closed	Fudan University	China
SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer NCT06465563 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma NCT06628310 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma	Phase 2	Active, closed	AbbVie	UK, USA, China
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma NCT06679985 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Active, closed	Coherus Oncology, Inc.	USA, China
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer NCT07071714 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment NCT07669051 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2	Active, closed	Shandong Cancer Hospital and Institute	China
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors NCT02671435 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Active, closed	MedImmune LLC	UK, USA
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. NCT02734004 · ClinicalTrials.gov ↗ · Ovarian, Breast, SCLC	Phase 1/2	Active, closed	AstraZeneca	UK, USA
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC NCT04068610 · Metastatic Microsatellite-stable Colorectal Cancer	Phase 1/2	Active, closed	MedImmune LLC	USA
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 · ClinicalTrials.gov ↗ · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Active, closed	Genmab	UK, USA, China
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) NCT04524871 · Advanced Liver Cancers	Phase 1/2	Active, closed	Hoffmann-La Roche	USA, China
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers NCT04626635 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Active, closed	Regeneron Pharmaceuticals	USA
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors NCT05229497 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors	Phase 1/2	Active, closed	Akeso	China
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer NCT05609370 · ClinicalTrials.gov ↗ · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	Phase 1/2	Active, closed	BeiGene	USA, China
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer NCT05846867 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1/2	Active, closed	Akeso	China
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer NCT05904379 · ClinicalTrials.gov ↗ · Advanced Non-small-cell Lung Cancer	Phase 1/2	Active, closed	Akeso	China
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors NCT05951608 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Active, closed	Akeso	China
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors NCT06730750 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Active, closed	Bristol-Myers Squibb	USA
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors NCT03872947 · ClinicalTrials.gov ↗ · Solid Tumor, Colorectal Cancer, Cholangiocarcinoma	Phase 1	Active, closed	Toray Industries, Inc	USA
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation NCT04449874 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors	Phase 1	Active, closed	Genentech, Inc.	UK, USA
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab NCT05029882 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma	Phase 1	Active, closed	AbbVie	USA
Study of INCB123667 in Subjects With Advanced Solid Tumors NCT05238922 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1	Active, closed	Incyte Corporation	UK, USA
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. NCT05355701 · ClinicalTrials.gov ↗ · Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer	Phase 1	Active, closed	Pfizer	USA
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma NCT05460767 · ClinicalTrials.gov ↗ · Solid Tumors or Lymphoma	Phase 1	Active, closed	Innovent Biologics (Suzhou) Co. Ltd.	China
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) NCT05464030 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1	Active, closed	EMD Serono Research & Development Institute, Inc.	USA
First in Human Study of AZD9592 in Solid Tumors NCT05647122 · ClinicalTrials.gov ↗ · Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms	Phase 1	Active, closed	AstraZeneca	USA, China
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers NCT05891171 · ClinicalTrials.gov ↗ · Advanced Cancer, Advanced Malignancies, Bladder Cancer	Phase 1	Active, closed	Arcus Biosciences, Inc.	USA
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer NCT06328738 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors	Phase 1	Active, closed	Enliven Therapeutics	USA
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors NCT06544655 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Active, closed	Bristol-Myers Squibb	USA
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors NCT06571422 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors	Phase 1	Active, closed	Shanghai Junshi Bioscience Co., Ltd.	China
JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC NCT06838338 · Colorectal Cancer	Phase 1	Active, closed	Jian Li	China
A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects NCT07340476 · ClinicalTrials.gov ↗ · Healthy Male Subjects	Phase 1	Active, closed	Akeso	China
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery NCT06117891 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Observational	Active, closed	Bayer	USA, China
Atezolizumab Plus Bevacizumab With HCC and HBV Infection NCT04180072 · ClinicalTrials.gov ↗ · Carcinoma, Hepatocellular	Not applicable	Active, closed	National Health Research Institutes, Taiwan	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Bevacizumab across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

11 single-substance products containing Bevacizumab on the HPRA medicines list.

Abevmy 25 mg/mL concentrate for solution for infusionBiosimilar Collaborations Ireland Limited · EU/1/20/1515/001-005
Alymsys 25 mg/mL concentrate for solution for infusionMabxience Research, S.L. · EU/1/20/1509/001-002
Avastin 25 mg/ml Concentrate for solution for infusionRoche Registration Limited · EU/1/04/300/1-2
Avastin 25 mg/ml concentrate for solution for infusionRoche Registration GmbH · EU/1/04/300/001-002
Aybintio 25 mg/ml concentrate for solution for infusionSamsung Bioepis NL B.V. · EU/1/20/1454/001

All 11 Irish products →

Supply shortages

ZirabevEU (EMA) · Shortage resolved · first published 17 Jan 2025

EU shortages US shortages German shortages

Conditions studied with Bevacizumab

371 conditions

Colorectal Cancer31 Ovarian Cancer25 Hepatocellular Carcinoma24 Advanced Solid Tumors20 Fallopian Tube Cancer14 Metastatic Colorectal Cancer13 Biliary Tract Cancer12 Colorectal Neoplasms11 Non-Small Cell Lung Cancer11 Pancreatic Cancer11 Gastric Cancer10 Pancreatic Ductal Adenocarcinoma8

All 371 conditions

Condition (as registered)	Trials
Colorectal Cancer	31
Ovarian Cancer	25
Hepatocellular Carcinoma	24
Advanced Solid Tumors	20
Fallopian Tube Cancer	14
Metastatic Colorectal Cancer	13
Biliary Tract Cancer	12
Colorectal Neoplasms	11
Non-Small Cell Lung Cancer	11
Pancreatic Cancer	11
Gastric Cancer	10
Pancreatic Ductal Adenocarcinoma	8
Esophageal Squamous Cell Carcinoma	8
Cervical Cancer	7
Metastatic Colorectal Cancer (CRC)	7
Advanced Solid Tumor	7
Colorectal Cancer Metastatic	7
Primary Peritoneal Cancer	6
Head and Neck Squamous Cell Carcinoma	6
Immunotherapy	6
Cancer	5
Neoplasms	5
Solid Tumor	5
Chemotherapy	5
Breast Cancer	5
Ovarian Neoplasms	4
Peritoneal Cancer	4
Endometrial Cancer	4
Solid Tumors	4
PDAC	4
Hepatocellular Carcinoma (HCC)	4
Gastroesophageal Adenocarcinoma	4
Rectal Cancer	4
Gastroesophageal Junction Adenocarcinoma	4
Esophageal Adenocarcinoma	4
Neoadjuvant Therapy	4
NSCLC	4
Rectal Adenocarcinoma	3
Colorectal Adenocarcinoma	3
Gastrointestinal Neoplasms	3
Glioblastoma	3
Solid Tumor, Adult	3
Advanced Breast Cancer	3
CRC	3
Epithelial Ovarian Cancer	3
Primary Peritoneal Carcinoma	3
Lung Cancer	3
Non-small Cell Lung Cancer	3
Recurrent Glioblastoma	3
Liver Metastases	3
Bevacizumab	3
Colorectal Cancer (CRC)	3
Non Small Cell Lung Cancer	3
Gastric Adenocarcinoma	3
Melanoma	3
HER2-positive Gastric Cancer	3
Fallopian Tube Neoplasms	2
Peritoneal Neoplasms	2
Neoplasm Metastasis	2
Metastatic Breast Cancer	2
CRC (Colorectal Cancer)	2
Metastatic Solid Tumors	2
Lung Adenocarcinoma	2
Carcinoma, Non-Small-Cell Lung	2
mCRC	2
MSS Metastatic Colorectal Cancer	2
Platinum-sensitive Ovarian Cancer	2
Bladder Cancer	2
Platinum-Sensitive Ovarian Cancer	2
Unresectable Hepatocellular Carcinoma	2
Acute Respiratory Distress Syndrome (ARDS)	2
ARDS	2
ARDS (Acute Respiratory Distress Syndrome)	2
Acute Respiratory Distress Syndrome	2
Intestinal Neoplasms	2
Neoplasms by Site	2
Metastatic Solid Tumor	2
Advanced Ovarian Cancer	2
Advanced Colorectal Cancer	2
High-Risk Cancer	2
MSS	2
Advanced Solid Tumour	2
Advanced Malignant Solid Tumors	2
Colorectal Liver Metastases	2
Advanced Malignancies	2
Breast Neoplasm	2
TNBC, Triple Negative Breast Cancer	2
Brain Metastasases	2
Colorectal Cancer Liver Metastasis	2
Cadonilimab	2
Chemotherapy Effect	2
Locally Advanced Rectal Cancer	2
Non-small Cell Lung Cancer (NSCLC)	2
Brain Metastases	2
Pancreatic Ductal Adenocarcinoma (PDAC)	2
Glioma	2
Biliary Tract Cancer (BTC)	2
HCC - Hepatocellular Carcinoma	2
RAS Mutation	2
ctDNA	2
Metastatic Pancreatic Cancer	2
Metastatic Pancreatic Adenocarcinoma	2
Urinary Bladder Neoplasms	2
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer	2
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer	2
Metastatic Gastric Adenocarcinoma or Cancer	2
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma	2
Gastroesophageal Junction (GEJ) Adenocarcinoma	2
Thyroid Cancer	2
Metastatic Gastric Adenocarcinoma	2
Esophageal Cancer	2
PDAC - Pancreatic Ductal Adenocarcinoma	2
Advanced Malignant Tumors	2
Nasopharyngeal Carcinoma	2
Small Cell Lung Cancer	2
AK112	2
Triple-Negative Breast Cancer (TNBC)	2
Non-Squamous Non-small Cell Lung Cancer	2
Carcinoma, Ovarian Epithelial	1
Colon Adenocarcinoma	1
Ewing Sarcoma	1
Metastatic Castration-resistant Prostate Cancer	1
Untreated, Unresectable, or Metastatic Colorectal Cancer	1
Tumours, Gynecological	1
Lung Squamous Cell Carcinoma	1
Stomach Neoplasms	1
Ovarian Cancer Recurrent	1
Ovarian	1
Breast	1
SCLC	1
Gastric Cancers	1
Metastatic Microsatellite-stable Colorectal Cancer	1
Ras-mutated Metastatic Colorectal Cancer	1
Advanced Liver Cancers	1
Micro Satellite Stable Colorectal Cancer	1
Gastric/Esophageal Cancer	1
Refractory Metastatic Colorectal Cancer	1
Diffuse Astrocytoma, IDH-Mutant	1
Glioblastoma, IDH-wildtype	1
Brain Metastases, Adult	1
HER2 Mutation-Related Tumors	1
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	1
PSOC	1
Advanced Solid Tumours	1
Carcinoma Non-small Cell Lung	1
Head and Neck Neoplasms	1
Metastatic Hepatocellular Carcinoma	1
Local Advanced Hepatocellular Carcinoma	1
Alpha-fetoprotein (AFP)-Producing Gastric Cancer	1
Extragonadal Yolk Sac Tumors	1
Endometrial Neoplasms	1
Uterine Cervical Neoplasms	1
Cholangiocarcinoma	1
Gynecologic Cancers	1
Primary Peritoneal Cancer (PSOC)	1
KRAS/NRAS Mutation	1
Locally Advanced Solid Tumor	1
Neoadjuvant	1
Advanced Microsatellite Stable Colorectal Cancer	1
Digestive System Neoplasms	1
Unresectable Metastatic Colorectal Cancer	1
Metastatic Breast Cancer (HR+/ HER2-)	1
Metastatic Colorectal Adenocarcinoma	1
PROC	1
Platinum Resistant Ovarian Cancer	1
Age-Related Macular Degeneration	1
Neovascular Age-related Macular Degeneration	1
Wet Macular Degeneration	1
BRVO - Branch Retinal Vein Occlusion	1
High Grade Epithelial Ovarian Cancer	1
High Grade Serous Ovarian Cancer	1
Platinum-resistant Ovarian Cancer	1
Platinum-refractory Ovarian Cancer	1
Soft Tissue Sarcoma (STS)	1
Platinum-resistant Ovarian Cancer (PROC)	1
Biliary Tract Cancers	1
Platinum-sensitive Relapsed Epithelial Ovarian Cancer	1
Platinum-sensitive Relapsed Fallopian Tube Cancer	1
Platinum-sensitive Relapsed Primary Peritoneal Cancer	1
DIPG	1
Advanced Unresectable Hepatocellular Carcinoma	1
Microsatellite Stable (MSS) Colorectal Cancer (CRC)	1
Recurrent Rectal Cancer	1
Triple-negative Breast Cancer	1
TNBC	1
Brain Metastasis	1
Non-squamous NSCLC	1
Targeted Therapy	1
HER2 + Breast Cancer	1
Advanced Hepatocellular Carcinoma	1
Ovarian Clear Cell Carcinoma	1
Platinum-sensitive Recurrent Ovarian Cancer	1
Oligodendroglioma	1
Hepato Cellular Carcinoma (HCC)	1
Brain Glioma	1
HER2-low Breast Cancer	1
First-line Treatment	1
Recurrent or Metastatic Cervical Cancer	1
Stage III Non-small Cell Lung Cancer	1
Solid Tumors or Lymphoma	1
Hormone Receptor Positive Tumor	1
HER2-negative Breast Cancer	1
Colorectal Cancer Recurrent	1
Ovarian Cancers	1
Platinum-resistant Recurrent Ovarian Cancer (PROC)	1
Hepatic Portal Vein Tumor Invasion	1
Tumor Thrombus	1
Secondary Malignant Neoplasm of Liver	1
PD-(L)1	1
CTLA-4	1
Advanced Melanoma	1
Iparomlimab	1
Liver Cancer Stage IV	1
Pulmonary Metastases	1
Carcinoma, Hepatocellular	1
Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor	1
Unresectable Advanced or Metastatic Colorectal Cancer	1
Multiple Brain Metastases in Lung Adenocarcinoma	1
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)	1
NSCLC (Non-small Cell Lung Cancer)	1
EGFR Activating Mutation	1
Resectable Lung Non-Small Cell Carcinoma	1
Colorectal Neoplasms Malignant	1
Neoplasm, Metastatic	1
High Grade Serous Adenocarcinoma of Ovary	1
High Grade Endometrioid Ovarian Cancer	1
Colo-rectal Cancer	1
Third-line and Beyond Therapy	1
TAS 102	1
Breast Cancer With Brain Metastasis	1
HER2-low Expressing Breast Cancer	1
pMMR/MSS Adenocarcinoma of the Colon or Rectum	1
ESCC	1
EGFR Mutation-Positive Lung Cancer	1
Leptomeningeal Metastases	1
Gastric/Gastroesophageal Junction Adenocarcinoma	1
Oesophageal Cancer	1
Metastatic Colorectal Cancer With Left-sided Primary Tumor	1
Hepatecellular Carcinoma	1
RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin	1
Type VP3/4 Portal Vein Tumor Thrombosis	1
Metastatic Colorectal Carcinoma	1
Astrocytoma of Brain	1
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)	1
Advanced Hepatocellular Carcinoma (HCC)	1
Breast Cancer Metastatic	1
Breast Cancer Brain Metastases	1
Advan'ce'd	1
Advanced	1
Radiotherapy, Intensity-Modulated	1
Colorectal Cancer Stage IV	1
BRAF V600 Colorectal Cancer	1
Mesothelioma	1
Platinum Sensitive Ovarian Cancer (PSOC)	1
TNBC - Triple-Negative Breast Cancer	1
Liver Transplant; Complications	1
Hepatocarcinoma	1
Recurrent Osteosarcoma	1
Microsatellite Stable Colorectal Carcinoma	1
Advanced or Metastatic Non-small Cell Lung Cancer	1
Acute Leukemia	1
Solid Cancer	1
Advanced HBV-Related Hepatocellular Carcinoma	1
Liposomal Irinotecan	1
Second-Line	1
Bevacizimab	1
HHT	1
Metastatic Pancreatic Ductal Adenocarcinoma	1
Neuroendocrine Tumors	1
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma	1
Colorectal Carcinoma	1
GEJ Adenocarcinoma	1
Urothelial Cancer	1
Pancreatic Adenocarcinoma	1
Advanced Cancer	1
Pharmacokinetics of Zolbetuximab	1
Gastro-esophageal Junction (GEJ) Cancer	1
Pharmacokinetics of Oxaliplatin	1
Non-Small-Cell Lung Cancer	1
Advanced or Metastatic Colorectal Cancer	1
Rectal Neoplasms	1
Pembrolizumab	1
EBV Infection	1
Stage II Nasopharyngeal Carcinoma AJCC v7	1
Stage III Nasopharyngeal Carcinoma AJCC v7	1
Stage IVA Nasopharyngeal Carcinoma AJCC v7	1
Pancreatic Cancer Metastatic to Liver	1
Advanced Solid Tumors Cancer	1
Unresectable/Metastatic Gastric Cancer	1
Second Line Treatment	1
Tyrosine Kinase Inhibitor	1
Metastatic Gastroesophageal Junction Adenocarcinoma	1
Peritoneal Carcinomatosis	1
Gastric Neoplasms	1
Gastroesophageal Junction Cancer	1
Pancreatic Cancer Metastatic	1
Recurrent Head and Neck Squamous Cell Carcinoma	1
HER2-positive Breast Cancer	1
HER2 Positive Solid Tumors	1
HER2 Amplification	1
Gastroesophageal Junction	1
Esophageal Neoplasms	1
Advanced Unresectable Gastric Adenocarcinoma	1
Advanced Gastroesophageal Adenocarcinoma	1
Locally Advanced or Metastatic Solid Tumors	1
Colon Cancer	1
PTC	1
Locally Advanced Thyroid Gland Carcinoma	1
Oral Squamous Cell Carcinoma	1
Gastric Cancer Stage IV	1
Resectable Colon Cancer	1
MSI-H/dMMR Colorectal Cancer	1
Non-small Cell Lung Cancer Stage IIIB/IV	1
Head and Neck Squamous Cell Carcinoma (HNSCC)	1
Intrahepatic Cholangiocarcinoma (Icc)	1
Metastasis	1
GC/GEJC	1
Liver Metastases From Colorectal Cancer (mCRC)	1
Neoplasms, Lung	1
Advanced Non-small Cell Lung Cancer	1
Metastatic Breast Cancer ( HER2 Negative)	1
RCT	1
Salivary Gland Carcinoma	1
Precision Therapy	1
Head and Neck Squamous Cell Carcinoma HNSCC	1
LOCALLY ADVANCED CERVICAL CANCERS	1
PD-1 Inhibitors	1
Immune Checkpoint Inhibitors (ICIs)	1
Radiation	1
Breast Tumors	1
NSCLC (Advanced Non-small Cell Lung Cancer)	1
SCLC, Recurrent	1
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)	1
Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)	1
Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	1
Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	1
Malignant Solid Tumor	1
Non-Small Cell Lung Cancer (NSCLC)	1
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer	1
Esophageal Squamous Cell Cancer	1
Siewert Type 1 GEJ Cancer	1
Leucogen	1
Myelosuppression	1
Gastrointestinal Cancer	1
Metastatic Gastric Cancer	1
Unresectable Gastric Carcinoma	1
Leptomeningeal Metastasis	1
Intrathecal Drug Delivery	1
Advanced Non-small Cell Lung Cancer (NSCLC)	1
Advanced Non-small-cell Lung Cancer	1
Pancreas Cancer	1
Pancreas Cancer, Duct Cell Adenocarcinoma	1
Advanced Non Small Cell Lung Cancer (NSCLC)	1
Healthy Male Subjects	1
Urothelial Carcinoma (UC)	1
Lung Cancer, Non-Small Cell	1
Metastatic Triple-negative Breast Cancer	1
Locally Advanced Triple-negative Breast Cancer	1
Colorectal Cancer With Hepatic Metastases	1
Mucosal Melanoma	1
Metastatic Melanoma	1
Metastatic Cancer	1
HCC	1
Neuroendocrine Cancer	1
Gastric or Gastroesophageal Junction Adenocarcinoma	1
Recurrent Ovarian Cancer	1
Advanced Solid Tumor Cancer	1
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	1
Respiratory Tract Neoplasms	1
Thoracic Neoplasms	1
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	1

By country register

Register	Trials	Recruiting
Clinical trials in China	343	209
Clinical trials in USA	164	108
Clinical trials in UK	63	43
Clinical trials in India	16	9
Clinical trials in Ireland	12	8

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Bevacizumab trials

How many clinical trials are testing Bevacizumab?

431 current trials in our China, USA, UK, India and Ireland registers name Bevacizumab (also registered as 5-Fluorouracil) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Bevacizumab trials recruiting patients?

Yes. 266 of the 431 trials are recruiting: 209 with sites in China, 108 with sites in USA, 43 with sites in UK, 9 with sites in India and 8 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Bevacizumab clinical trials?

Akeso (30), Fudan University (25), AstraZeneca (21) and Sun Yat-sen University (21), among 169 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Bevacizumab licensed in Ireland?

Yes. The HPRA medicines list includes 11 single-substance products containing Bevacizumab, for example Abevmy 25 mg/mL concentrate for solution for infusion (Biosimilar Collaborations Ireland Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Bevacizumab shortage?

The registers we track list 1 entry for Bevacizumab: Zirabev (EU: shortage resolved). Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Bevacizumab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Bevacizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Bevacizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Bevacizumab clinical trials